Analysis of Non-Coding RNA-Mediated Regulation in TME

Non-coding RNA-mediated regulation offers a novel approach to understanding and potentially altering the tumor microenvironment (TME). At Alfa Cytology, we are committed to offering exceptional services to analyze non-coding RNA-mediated regulation in the TME.

The Role of Non-Coding RNA-Mediated Regulation in TME

One of the key players in RNA-mediated regulation is non-coding RNA molecules, which do not code for proteins but instead have regulatory functions. Two major classes of non-coding RNAs are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). These RNA molecules can modulate gene expression by interacting with messenger RNAs (mRNAs) or other regulatory proteins. In the TME, dysregulation of non-coding RNAs is commonly observed and can have profound effects on tumor biology. Certain miRNAs and lncRNAs are upregulated or downregulated in cancer cells, leading to altered gene expression patterns. These changes can affect various aspects of tumor development, including proliferation, angiogenesis, invasion, and immune evasion. Furthermore, lncRNAs have also emerged as potential targets for therapeutic intervention in the TME. Some lncRNAs have been identified to play critical roles in tumor progression and metastasis. Targeting these lncRNAs using antisense oligonucleotides or small interfering RNAs (siRNAs) holds promise for developing novel cancer therapies.

Fig. 1 Illustration of non-coding RNAs in the modulation of the TIME during tumor growth and progression. (Mansouri S, et al., 2022Pandey PR, et al., 2022)

Analysis of Non-Coding RNA-Mediated Regulation in TME

At Alfa Cytology, we offer a range of cutting-edge services for the analysis of non-coding RNA-mediated regulation in the TME. Our expertise in RNA sequencing, bioinformatics analysis, and molecular biology allows us to provide comprehensive insights into the role of RNA in tumor biology. Our services include, but are not limited to:

• Exploring lncRNAs in TME for Diagnostic Markers
  We utilize RNA sequencing (RNA-Seq) to identify differentially expressed lncRNAs in the TME of various cancer types, thereby highlighting their potential as diagnostic markers. Furthermore, we can assist our clients in assessing the dysregulation of several lncRNAs associated with tumor-infiltrating immune cells, implicating their involvement in immune regulation within the TME.
• Identifying circRNA-Regulated Pathways in TME
  By utilizing bioinformatics tools, we can identify key signaling pathways regulated by circRNAs in the TME. This enables us to support our clients in uncovering novel circRNA-miRNA-mRNA interaction networks that are involved in tumor progression and provide potential therapeutic targets.
• Unraveling RNA Function in TME
  To ensure the reliability of our findings, we offer validation studies using various molecular biology techniques. We employ quantitative real-time PCR (qRT-PCR) to validate differentially expressed RNAs identified through RNA-Seq. Additionally, we conduct functional studies, such as cell-based assays and animal models to elucidate the functional role of specific RNA molecules in the TME.

The Advantages of Our Non-Coding RNA-Mediated Regulation Analysis

• Through comprehensive analysis, including differential expression analysis, pathway enrichment, and functional annotation, we extensively explore the regulatory landscape in order to uncover novel insights.
• We offer customized services to meet your specific requirements. Whether it's selecting the appropriate RNA sequencing platform, designing tailored bioinformatics pipelines, or conducting validation studies using various molecular biology techniques, we ensure that our services align with your research goals.

By unraveling the complex network of RNA molecules and their interactions within the TME, researchers can uncover new insights into tumor biology. At Alfa Cytology, we are committed to integrating RNA-Seq and bioinformatics analysis to provide our clients with a comprehensive understanding of regulatory networks within the TME. Contact us today to learn more about our RNA-mediated regulation analysis services and how they can propel your research forward.

Reference

1. Pandey PR, et al. RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Mol Cancer, 2022;21(1):58.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.